Ecolab Inc. — Q2 2020 Form 10-Q Summary
Business context and reporting period
Quarter ended June 30, 2020; comparisons are with Q2 2019 unless stated otherwise. Ecolab provides cleaning, sanitation, water, energy and related services. The COVID-19 pandemic sharply disrupted restaurant, hospitality and entertainment demand while increasing demand in parts of healthcare and life sciences.
On June 3, Ecolab completed the separation of its Upstream Energy business through the ChampionX transaction. ChampionX results are presented as discontinued operations for all periods, and Ecolab now reports Global Industrial, Global Institutional, Global Healthcare and Life Sciences, and Other.
Financial performance
| Metric | Q2 2020 | Prior-year comparison |
|---|---|---|
| Net sales | $2.686 billion | Down 15% reported; down 13% at fixed currency |
| Operating income | $192 million | Down 59%; adjusted operating income down 42% |
| Operating margin | 7.1% reported; 10.7% adjusted | 14.7% reported; 15.7% adjusted |
| Continuing-operations net income attributable to Ecolab | $129 million | Down 62%; adjusted net income down 49% to $190 million |
| Diluted EPS from continuing operations | $0.44 reported; $0.65 adjusted | Down 63% reported; adjusted EPS down 49% |
| Gross margin | 39.1% reported; 40.1% adjusted | 43.8% reported; 44.1% adjusted |
For the first six months, sales were $5.706 billion, down 6% reported and 5% at fixed currency. Operating income was $568 million, down 27%; continuing-operations net income attributable to Ecolab was $421 million, down 29%; diluted continuing-operations EPS was $1.44, down 29%.
Segment trends were uneven: Q2 fixed-currency sales fell 35% in Global Institutional and 19% in Other, while Global Industrial declined 2%. Global Healthcare and Life Sciences grew 22%. Institutional operating income was a $37 million loss, reflecting the severe volume decline; Industrial and Healthcare and Life Sciences operating income increased.
Cash flow, debt and liquidity
- First-half cash from operating activities of continuing operations was $640 million, down $124 million from 2019. Capital expenditures were $251 million.
- At June 30, cash and cash equivalents were $1.369 billion. Total debt was approximately $7.287 billion and net debt approximately $5.918 billion; net debt to trailing EBITDA was 2.4 times.
- Short-term debt was $535 million, including $517 million of commercial paper. Ecolab reported no borrowings under its $2.0 billion multi-year credit facility or $500 million 364-day facility and stated it was in compliance with debt covenants.
- First-half cash flows included $769 million of long-term debt proceeds, $300 million of debt repayments and $283 million of dividends paid.
Material changes, outlook and risks
- Pandemic impact: Management expected continued adverse effects on 2020 results and operating cash flow, particularly in restaurants, lodging and entertainment, and said the full impact could not yet be estimated. A one-time suspension of approximately $38 million in lease billings was provided to certain restaurant customers.
- Special items: Continuing-operations special gains and charges totaled $97 million in Q2. Items included a $28.6 million impairment of a minority equity-method investment, a $16.1 million loss and related fees on the Holchem sale, COVID-related employee pay costs partly offset by government assistance, European healthcare product-recall charges, and legal charges/reserves. These amounts make reported and adjusted results materially different.
- ChampionX separation: The transaction produced a $2.138 billion loss on separation, driving the reported Q2 net loss attributable to Ecolab of $2.035 billion; continuing operations remained profitable. The separation included $527 million cash received and approximately 5.0 million Ecolab shares exchanged. The transaction loss is included in discontinued operations.
- Portfolio actions: Ecolab acquired CID Lines for approximately $507 million cash and sold Holchem for $106.6 million consideration, including cash and notes receivable.
- Restructuring: Accelerate 2020 was expected to be completed by year-end 2020, with total anticipated costs of $215 million and estimated annual continuing-operations savings of $270 million by 2021. The company reported $151 million in cumulative savings and $72.5 million remaining liability at quarter-end.
- Credit and legal exposure: Allowance for doubtful accounts rose to $86.3 million from $55.5 million at year-end; management attributed higher bad-debt expense primarily to pandemic-related uncertainty, especially among Institutional customers. The company disclosed ongoing litigation and environmental matters, while stating it did not then expect material losses beyond accrued amounts.
- Formal guidance: The filing provides no specific full-year earnings or sales forecast; management said the pandemic’s duration and effects remained uncertain. It expected to fund foreseeable cash needs through operations and, as needed, borrowing.
Most important facts for investors to verify
- How quickly restaurant, hospitality and other Institutional demand recovers, and whether pandemic-related pressure on collections and bad debts continues.
- The reconciliation and persistence of non-GAAP adjusted results, including the special charges, product recall costs, legal reserves and investment impairment.
- Post-separation comparability and continuing obligations under ChampionX transition and product-supply agreements.
- Debt, commercial-paper usage, cash generation and progress against the 2.4x net debt-to-EBITDA measure.
- Whether Accelerate 2020 achieves its stated savings and completion targets, and whether environmental, litigation or other contingencies change.
The interim financial statements were reviewed by PwC, not audited; the auditor reported no material modifications needed based on its review procedures.